Dr Reddy’s Laboratories has entered into a definitive agreement to acquire a select portfolio of the established products business of UCB, in the territories of India, Nepal, Sri Lanka and Maldives. The acquired business is being sold on a slump sale basis. The transaction includes around 350 employees engaged in operations of the India Business.
The revenue of the acquired business is around Rs 150 crore for calendar year 2014. The acquisition of UCB’s existing brand equity in the areas of Dermatology, Respiratory and Pediatrics diseases will further expand Dr Reddy’s therapy footprint into these fast growing areas.
Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
Dr. Reddys Laboratories is currently trade at Rs. 3545.00, up by 57.55 points or 1.65% from its previous closing of Rs. 3487.45 on the BSE.
The revenue of the acquired business is around Rs 150 crore for calendar year 2014. The acquisition of UCB’s existing brand equity in the areas of Dermatology, Respiratory and Pediatrics diseases will further expand Dr Reddy’s therapy footprint into these fast growing areas.
Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
Dr. Reddys Laboratories is currently trade at Rs. 3545.00, up by 57.55 points or 1.65% from its previous closing of Rs. 3487.45 on the BSE.
No comments:
Post a Comment